Dr. Nipun Verma

Excellent study

Beautiful lines..

Let’s rethink cirrhosis management! 🔄💬 #LiverDisease #Hepatology #Cirrhosis #PrecisionMedicine

💡 Should NAD patients be prioritized for earlier intervention? Could targeting necroptosis & pyroptosis prevent disease progression?

🔬 Key findings:
✔️ NAD patients have increased cell death (RIPK3, Gasdermin-D) but no systemic inflammation
✔️ 55% progress to AD within 12 months—leading to worse survival
✔️ Low IGF-1, high bilirubin, severe ascites predict progression @easlnews.bsky.social

🚨 New Insights in Cirrhosis! 🚨

www.journal-of-hepatology.eu/article/S016...

Our study reveals Non-Acute Decompensation (NAD) is a distinct clinical state, different from compensated cirrhosis & acute decompensation (AD) @rajivjalan.bsky.social @jhepatology.bsky.social @akashroyy.bsky.social

@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky

Systemic inflammation🔥(SI) is a major driver of #liver disease progression in patients with decompensated #cirrhosis.
Dr. Lukas Hartl now demonstrated in #JHEPReports that #TIPS not only controls #PH-related decompensation but also effectively and sustainedly decrease #SI (#IL6 levels.
🔗 t.ly/A39-U

Please delve deeper into “social” drinking with your patients, especially in those with evidence of liver disease. More often than not, drinking that is considered socially acceptable is harmful to the liver. Sometimes a brief intervention/educational moment is enough to save a liver! #liversky

🆕Article in press❕

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH

Full text here👉https://bit.ly/4iucrzV

More information here👉https://bwnews.pr/4hadNie

#OpenAccess
#LiverSky

Spicy!

Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors

@juancarlosqvelez.bsky.social

doi.org/10.1016/j.ek...
#nephsky #liversky

Highlighting role of hepatology in the spectrum of HCC care
In this study
Impact of liver decom on clinical outcomes on atezobeva
📌OS better in CP A vs CP B
📌No differences in TTP/safety
📌Liver decomp: 28% CP A vs 51% CP B
📌41% resume after decomp
#Liversky
www.cghjournal.org/article/S154...

Excellent summary and discussion Dr Atoosa..💐Thanks for your presentation

What an honor to be speaking at Hot Topics at AASLD 2024 hosted by ILBS invited by one and only Dr. Shiv Sarin :)
#liversky

🚀 AI & ML are transforming liver disease care!

🔬our @akashroyy.bsky.social review explores how machine learning enhances diagnosis & outcome prediction in alcohol-related & metabolic dysfunction-associated steatotic liver diseases (MASLD). 🔍

🔗 oaepublish.com/articles/mtod.…

#AI #Liver

A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis - Journal of Translational Medicine Background Patient heterogeneity poses significant challenges for managing individuals and designing clinical trials, especially in complex diseases. Existing classifications rely on outcome-predictin...

🔵 ClustALL paper: This innovative clustering method addresses patient heterogeneity in acutely decompensated #cirrhosis, identifying subgroups with prognostic value to improve trials and personalized care. Read more: translational-medicine.biomedcentral.com/articles/10....
#LiverSky

Google’s AI Co-Scientist vs. OpenAI’s Deep Research vs. Perplexity’s Deep Research: A Comparison of AI Research Agents Rapid advancements in AI have brought about the emergence of AI research agents—tools designed to assist researchers by handling vast amounts of data, automating repetitive tasks, and even generating ...

www.unite.ai/googles-ai-c... #AI #artificialintelligence

Fascinating discussion on PSVD, NCPF, Idiopathic portal hypertension ongoing in @jhepatology.bsky.social @valdig.bsky.social @ebtapper.bsky.social would be worth a skytutorial